Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) CMO Jeffrey Chodakewitz sold 1,796 shares of the firm’s stock in a transaction dated Wednesday, August 2nd. The shares were sold at an average price of $154.13, for a total value of $276,817.48. Following the transaction, the chief marketing officer now owns 116,220 shares in the company, valued at $17,912,988.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Jeffrey Chodakewitz also recently made the following trade(s):

  • On Thursday, August 3rd, Jeffrey Chodakewitz sold 5,390 shares of Vertex Pharmaceuticals stock. The shares were sold at an average price of $154.17, for a total value of $830,976.30.
  • On Friday, July 21st, Jeffrey Chodakewitz sold 46,733 shares of Vertex Pharmaceuticals stock. The shares were sold at an average price of $160.96, for a total value of $7,522,143.68.
  • On Monday, July 17th, Jeffrey Chodakewitz sold 573 shares of Vertex Pharmaceuticals stock. The shares were sold at an average price of $129.85, for a total value of $74,404.05.
  • On Monday, July 3rd, Jeffrey Chodakewitz sold 3,438 shares of Vertex Pharmaceuticals stock. The shares were sold at an average price of $127.80, for a total value of $439,376.40.
  • On Wednesday, June 21st, Jeffrey Chodakewitz sold 5,157 shares of Vertex Pharmaceuticals stock. The shares were sold at an average price of $132.87, for a total value of $685,210.59.

Vertex Pharmaceuticals Incorporated (VRTX) opened at 154.54 on Monday. Vertex Pharmaceuticals Incorporated has a 1-year low of $71.46 and a 1-year high of $167.85. The company has a market cap of $38.96 billion, a PE ratio of 148.45 and a beta of 1.77. The stock has a 50 day moving average of $137.73 and a 200-day moving average of $111.96.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its earnings results on Wednesday, July 26th. The pharmaceutical company reported $0.39 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.06 by $0.33. Vertex Pharmaceuticals had a net margin of 12.05% and a return on equity of 4.64%. The firm had revenue of $544.10 million for the quarter, compared to analyst estimates of $489.95 million. During the same quarter in the prior year, the business posted $0.24 EPS. The business’s revenue was up 26.1% compared to the same quarter last year. On average, equities research analysts predict that Vertex Pharmaceuticals Incorporated will post $1.59 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This article was first posted by Daily Political and is owned by of Daily Political. If you are accessing this article on another website, it was illegally stolen and reposted in violation of United States and international copyright and trademark law. The correct version of this article can be accessed at https://www.dailypolitical.com/2017/08/07/insider-selling-vertex-pharmaceuticals-incorporated-vrtx-cmo-sells-1796-shares-of-stock.html.

Several equities research analysts have recently issued reports on VRTX shares. Cowen and Company reaffirmed a “buy” rating on shares of Vertex Pharmaceuticals in a research report on Tuesday, August 1st. Zacks Investment Research downgraded Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday, April 10th. Jefferies Group LLC started coverage on Vertex Pharmaceuticals in a research report on Monday, July 10th. They issued a “buy” rating and a $155.00 price target on the stock. Credit Suisse Group raised their price target on Vertex Pharmaceuticals from $125.00 to $195.00 and gave the company an “outperform” rating in a research report on Wednesday, July 19th. Finally, Barclays PLC reaffirmed an “equal weight” rating and issued a $100.00 price target (up from $90.00) on shares of Vertex Pharmaceuticals in a research report on Sunday, April 23rd. Five investment analysts have rated the stock with a hold rating, twenty-two have assigned a buy rating and one has given a strong buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $162.88.

Several hedge funds and other institutional investors have recently made changes to their positions in VRTX. Korea Investment CORP raised its position in shares of Vertex Pharmaceuticals by 225.3% in the first quarter. Korea Investment CORP now owns 950 shares of the pharmaceutical company’s stock worth $104,000 after buying an additional 658 shares during the last quarter. Guardian Life Insurance Co. of America raised its stake in Vertex Pharmaceuticals by 0.6% in the first quarter. Guardian Life Insurance Co. of America now owns 956 shares of the pharmaceutical company’s stock valued at $105,000 after buying an additional 6 shares in the last quarter. Dupont Capital Management Corp purchased a new stake in Vertex Pharmaceuticals during the second quarter valued at about $186,000. FUKOKU MUTUAL LIFE INSURANCE Co raised its stake in Vertex Pharmaceuticals by 7.1% in the first quarter. FUKOKU MUTUAL LIFE INSURANCE Co now owns 1,500 shares of the pharmaceutical company’s stock valued at $164,000 after buying an additional 100 shares in the last quarter. Finally, State of Alaska Department of Revenue purchased a new stake in Vertex Pharmaceuticals during the second quarter valued at about $197,000. Hedge funds and other institutional investors own 93.13% of the company’s stock.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

Insider Buying and Selling by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.